Leukaemia Section

Short Communication

t(7;17)(q32-34;q23)

Jean-Loup Huret

Genetics, Dept Medical Information, UMR 8125 CNRS, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

Published in Atlas Database: August 2005

Online updated version: http://AtlasGeneticsOncology.org/Anomalies/t0717q33q23ID1402.html

DOI: 10.4267/2042/38270

This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence.

© 2006 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Clinics and pathology

Disease

Chronic myelogenous leukemia (CML) in accelerated phase (AP-CML).

Epidemiology

Only one case to date, a female patient, aged 40 at the time of the AP-CML.

Prognosis

Chronic phase of CML lasted 2 years before progression into an accelerated phase accompanied with the appearance of the t(7;17); 2 months later, a blast crisis occurred, and the patient died 9 months after the AP-CML, 33 months after initial diagnosis of CML.

Cytogenetics

Cytogenetics morphological

A t(9;22)(q34;q11) was, indeed, present.

Cytogenetics molecular

Cryptic translocation; recognized by multicolor FISH plus locus-specific FISH.

Genes involved and Proteins

Note: The gene involved on chromosome 7 is undefined, due to a lack of material for further analysis, but it seems to be a gene of the plexin family, with, perhaps, a sema domain, a plexin repeat, and an immunoglobulin-like plexin transcription factor domain.

MSI2

Location: 17q23.2

DNA / RNA

At least 15 exons; various splicing.

Protein

Possesses 2 RNA recognition motifs; likely to be a RNA binding protein; may play a role in RNA metabolism in the cytoplasm; the mouse homolog is ubiquitous, and particularly active in the brain development.

References


This article should be referenced as such: